Clinical Trial: Validation of the Utility of Rare Disease Intelligence Platform

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Validation of the Utility of Rare Disease Intelligence Platform: A Multicenter Cluster Clinical Trial

Brief Summary: The prevention and treatment of diseases via artificial intelligence represents an ultimate goal in computational medicine. The artificial intelligence for systematic clinical application has not yet been successfully validated. Currently, the main prevention strategy for rare diseases is to build specialized care centers. However, these centers are scattered, and their coverage is insufficient, resulting in inadequate health care among a large proportion of rare disease patients. Here, the investigators use "deep learning" to create CC-Cruiser, an intelligence agent involving three functional networks: "pick-up networks" for diagnostics, "evaluation networks" for risk stratification and "strategist networks" to provide assisted treatment decisions. The investigator also establish a cloud intelligence platform for multi-hospital collaboration and conduct clinical trial and website-based study to validate its versatility.

Detailed Summary:
Sponsor: Sun Yat-sen University

Current Primary Outcome: The proportion of accurate, mistaken and miss detection of CC-Cruiser. [ Time Frame: Up to 4 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Sun Yat-sen University

Dates:
Date Received: April 13, 2016
Date Started: January 2012
Date Completion:
Last Updated: April 21, 2016
Last Verified: April 2016